Skip to main content
. 2024 May 5;12(5):500. doi: 10.3390/vaccines12050500

Figure A23.

Figure A23

Risk ratio for breakthrough lower respiratory tract disease (LRTD) with 3 or more signs/symptoms after the delivery of respiratory syncytial virus (RSV) vaccine (I2 0.0%, 95% CI 0.0 to 89.6; tau2 0, 95% CI 0.0 to 6.872; Q = 0.65, p = 0.721) in follow up studies [48,61,85].